Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBT (2022 - 2026)

Indivior Pharmaceuticals has reported EBT over the past 5 years, most recently at $115.0 million for Q1 2026.

  • For Q1 2026, EBT rose 94.92% year-over-year to $115.0 million; the TTM value through Mar 2026 reached $295.0 million, up 4816.67%, while the annual FY2025 figure was $239.0 million, 1095.0% up from the prior year.
  • EBT for Q1 2026 was $115.0 million at Indivior Pharmaceuticals, up from $81.0 million in the prior quarter.
  • Over five years, EBT peaked at $115.0 million in Q1 2026 and troughed at -$256.0 million in Q4 2022.
  • A 5-year average of $14.4 million and a median of $58.0 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: tumbled 435.19% in 2023 and later soared 151.24% in 2025.
  • Year by year, EBT stood at -$256.0 million in 2022, then skyrocketed by 123.83% to $61.0 million in 2023, then crashed by 37.7% to $38.0 million in 2024, then surged by 113.16% to $81.0 million in 2025, then surged by 41.98% to $115.0 million in 2026.
  • Business Quant data shows EBT for INDV at $115.0 million in Q1 2026, $81.0 million in Q4 2025, and $37.0 million in Q3 2025.